Showing results (11-20 of 26) with videos related to

Sort By:
Pageof 3
Annales De Biologie Clinique|April 9, 2008
[Hemophagocytic syndrome and toxoplasmic primo-infection]P Y Briand, J P Gangneux, G Favaretto, et al.
Melanoma Research|May 3, 2001
Phase II randomized study of dacarbazine, carmustine, cisplatin and tamoxifen versus dacarbazine alone in advanced melanoma patientsV Chiarion Sileni, R Nortilli, S M Aversa, et al.
Cancer|May 27, 2003
Gemcitabine combined with carboplatin in patients with malignant pleural mesothelioma: a multicentric phase II studyAdolfo G Favaretto, Savina M L Aversa, Adriano Paccagnella, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|March 22, 2006
Phase II study of pemetrexed plus carboplatin in malignant pleural mesotheliomaGiovanni L Ceresoli, Paolo A Zucali, Adolfo G Favaretto, et al.
Acta Haematologica|September 4, 2004
Stanford V regimen plus consolidative radiotherapy is an effective therapeutic program for bulky or advanced-stage Hodgkin's diseaseSavina M L Aversa, Luigi Salvagno, Mariella Sorarù, et al.
The Oncologist|August 25, 2018
Retrospective Assessment of a Serum Proteomic Test in a Phase III Study Comparing Erlotinib plus Placebo with Erlotinib plus Tivantinib (MARQUEE) in Previously Treated Patients with Advanced Non-Small Cell Lung CancerConsuelo Buttigliero, Frances A Shepherd, Fabrice Barlesi, et al.
British Journal of Cancer|June 12, 2014
Prognostic factors in elderly patients with malignant pleural mesothelioma: results of a multicenter surveyG L Ceresoli, F Grosso, P A Zucali, et al.
Clinical Lung Cancer|January 15, 2014
Rationale and design of MILES-3 and MILES-4 studies: two randomized phase 3 trials comparing single-agent chemotherapy versus cisplatin-based doublets in elderly patients with advanced non--small-cell lung cancerCesare Gridelli, Antonio Rossi, Massimo Di Maio, et al.
British Journal of Cancer|July 18, 2013
Phase II study of pemetrexed and carboplatin plus bevacizumab as first-line therapy in malignant pleural mesotheliomaG L Ceresoli, P A Zucali, M Mencoboni, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|April 4, 2014
Nondisruptive p53 mutations are associated with shorter survival in patients with advanced non-small cell lung cancerMiguel A Molina-Vila, Jordi Bertran-Alamillo, Amaya Gascó, et al.
Pageof 3